about
Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationshipsDefining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptorSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersThe tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptorsThe impact of GPCR structures on pharmacology and structure-based drug designLigand binding assays at equilibrium: validation and interpretationThe ANG-(1-7)/ACE2/mas axis in the regulation of nephron functionAllostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapesAllosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.G-protein-coupled receptor heteromers: function and ligand pharmacologyWhat systems can and can't doA selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learningDiscovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersThe Camerino symposium series (1978-2013): a privileged observatory of receptorology developmentDiversity and modularity of G protein-coupled receptor structuresNovel GPCR paradigms at the μ-opioid receptorRegulation of G protein-coupled receptors by allosteric ligandsRational approaches to improving selectivity in drug designDREADDs: novel tools for drug discovery and developmentExploring the role of receptor flexibility in structure-based drug discoveryAre cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic reviewDrugs for allosteric sites on receptorsG-protein-coupled receptors targeting: the allosteric approachPositive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medicationsEndogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments.Allosteric regulation of serine protease HtrA2 through novel non-canonical substrate binding pocket.An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligaseIdentification of a novel ligand binding site in phosphoserine phosphatase from the hyperthermophilic archaeon Thermococcus onnurineusGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesA new mechanism of allostery in a G protein-coupled receptor dimerCharacterization of an mGluR2/3 negative allosteric modulator in rodent models of depressionIn vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependencyEffects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalizationA unified view of "how allostery works"Chemical, target, and bioactive properties of allosteric modulationProperties of protein drug target classesMechanical gating of a mechanochemical reaction cascadePositive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse ElectrophilesEmerging Computational Methods for the Rational Discovery of Allosteric Drugs.
P2860
Q24297642-1F841025-5FED-4B21-A473-F83E5F8F088BQ24338567-A547285E-A5CF-402C-8DB3-D10F024C1407Q24605472-8F48229B-9F75-45D4-86BC-8EFA9B05B1C7Q24605967-FEB0497C-A99A-4DB2-B8A8-3AAB2C69A261Q24628661-1CBA54CA-4AA7-4329-AB00-4638B7D70F35Q24629851-CA3D3703-4E31-4BA5-9ECF-D8EDFECB5F29Q24633556-F9DDF867-3A41-4119-B441-50C64FC7F1BFQ24633877-7161F647-2FB4-4DF6-89CC-7E11D4F21D9EQ24649568-9BE2D682-89C7-42A2-ADF8-A042025FA128Q24653717-45B49045-B8E3-4519-9942-0E0687D3F613Q24654880-74C51B53-BCBE-40AA-BC43-493C006116E2Q24657785-9ACC7130-0F91-45A8-A245-9944DB17F9D8Q24657902-7E37F792-3FBA-47C5-97EB-F708237BFD27Q26748728-E3619C8C-B605-487B-95FB-C1921961FDFBQ26830483-232C1E4F-403A-4017-9C17-98960362CEA5Q26852976-E00EE386-BF24-4A42-A0B2-68746C4A56CAQ26864286-17668614-B886-44F3-B0CD-8401E04B0FC8Q26864384-DD744586-F439-46D5-AAB7-67D1279543BCQ26865357-B6ECEA34-918A-4924-AC1B-2CD53DB1ACBBQ26995396-4E15B10D-B554-47FA-AEE8-119F66C1BB3BQ27001129-533DB25E-8B4E-4660-BBF0-BBDB73A5AD5AQ27005619-9C94EFB7-2198-48DE-A315-C21BB081464EQ27006721-2EF1F26F-0756-4F36-9BE8-72D295AF1F7AQ27023311-B1FCF6BD-F50E-477C-9003-3F9645666A62Q27027736-B524541A-D13E-4E03-A8BD-8AB4EE4AF07FQ27308091-10692939-EA41-4909-924D-FB8BF01863DBQ27316788-E86ED3AD-89AF-46D8-A3E6-ACD1AD162A6BQ27662837-22E0E458-E773-4746-B355-1742B435AF04Q27683600-B16078E8-4FE7-46ED-B3BF-FE3101CA71C1Q28067465-D906A8D7-565E-4260-8D9F-F42021F9978CQ28245604-CD9CD6FC-6721-4612-9B17-01FF7E13A940Q28253233-50085432-E6BD-404D-9F32-4E9FFA935578Q28480533-D931D2C8-C037-4E8B-8C57-FB85EB321002Q28535151-70549515-E2F9-4395-9646-ED2F49173424Q28539606-6F902535-37CB-4615-8A4F-44A13EFE2C6BQ28541837-A38773A4-BCD7-4A23-AC13-8C5CC301CFC7Q28545197-C3AB6BCA-1755-4E69-ADDA-561B7C833552Q28821029-BDC3D5D7-0809-44F0-9FD5-EE580BE9C118Q28834277-EB0F31E1-B29D-46DB-B32D-521194D87B14Q30358225-21E6CA59-8C54-4642-BF49-3ADF24AAF1E4
P2860
description
im Februar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2007
@uk
name
Allosteric Modulation of G Protein–Coupled Receptors
@en
Allosteric Modulation of G Protein–Coupled Receptors
@nl
type
label
Allosteric Modulation of G Protein–Coupled Receptors
@en
Allosteric Modulation of G Protein–Coupled Receptors
@nl
prefLabel
Allosteric Modulation of G Protein–Coupled Receptors
@en
Allosteric Modulation of G Protein–Coupled Receptors
@nl
P1476
Allosteric modulation of G protein-coupled receptors
@en
P2093
Arthur Christopoulos
Lauren T May
P356
10.1146/ANNUREV.PHARMTOX.47.120505.105159
P577
2007-01-01T00:00:00Z